Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PCI Versus CABG: Comparative Effectiveness Study Funded By ARRA Grant

This article was originally published in The Gray Sheet

Executive Summary

The American College of Cardiology and Society of Thoracic Surgeons will study the comparative effectiveness of percutaneous coronary intervention and coronary artery bypass graft surgery with a $4 million NIH research grant, announced Oct. 2

You may also be interested in...

AHRQ, NIH Report To Congress On Comparative Effectiveness Spending Plans

Two Health and Human Services agencies will allocate about $250 million this year in comparative effectiveness research funds from the federal stimulus package; the remainder of the $1.1 billion comparative effectiveness money will be put to use in 2010

CABG Beats DES In SYNTAX Trial; Observers Expect Little Change In Practice

Analysts and physicians predict one-year results from the SYNTAX trial will have little short-term impact on demand for drug-eluting stents, even though the devices performed worse than coronary artery bypass graft (CABG) surgery in this seminal randomized trial

Finance Watch: Silverback, Kinnate, Sigilon Launch December’s First IPOs

Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts